CN114401990A - 用于调节髓系细胞炎性表型的抗psgl-1组合物和方法及其用途 - Google Patents

用于调节髓系细胞炎性表型的抗psgl-1组合物和方法及其用途 Download PDF

Info

Publication number
CN114401990A
CN114401990A CN202080055123.9A CN202080055123A CN114401990A CN 114401990 A CN114401990 A CN 114401990A CN 202080055123 A CN202080055123 A CN 202080055123A CN 114401990 A CN114401990 A CN 114401990A
Authority
CN
China
Prior art keywords
cells
macrophages
cell
agent
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080055123.9A
Other languages
English (en)
Chinese (zh)
Inventor
T·I·诺沃布兰塞瓦
I·费尔德曼
S·L·萨金斯基
J·A·瓦勒
B·奥努亚莱恩
R·芬尼西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viseo Pharmaceutical Co
Original Assignee
Viseo Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viseo Pharmaceutical Co filed Critical Viseo Pharmaceutical Co
Publication of CN114401990A publication Critical patent/CN114401990A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
CN202080055123.9A 2019-06-04 2020-06-02 用于调节髓系细胞炎性表型的抗psgl-1组合物和方法及其用途 Pending CN114401990A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962857169P 2019-06-04 2019-06-04
US62/857169 2019-06-04
US201962867569P 2019-06-27 2019-06-27
US62/867569 2019-06-27
US201962947948P 2019-12-13 2019-12-13
US62/947948 2019-12-13
US202063032214P 2020-05-29 2020-05-29
US63/032214 2020-05-29
PCT/US2020/035702 WO2020247371A1 (en) 2019-06-04 2020-06-02 Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Publications (1)

Publication Number Publication Date
CN114401990A true CN114401990A (zh) 2022-04-26

Family

ID=73651973

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080055123.9A Pending CN114401990A (zh) 2019-06-04 2020-06-02 用于调节髓系细胞炎性表型的抗psgl-1组合物和方法及其用途

Country Status (11)

Country Link
US (1) US12552873B2 (enExample)
EP (1) EP3980463A4 (enExample)
JP (2) JP7716992B2 (enExample)
KR (1) KR20220042055A (enExample)
CN (1) CN114401990A (enExample)
AU (1) AU2020288823A1 (enExample)
BR (1) BR112021024242A2 (enExample)
CA (1) CA3141334A1 (enExample)
IL (1) IL288510A (enExample)
TW (1) TW202110891A (enExample)
WO (1) WO2020247371A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
CA3141334A1 (en) * 2019-06-04 2020-12-10 Verseau Therapeutics, Inc. Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
GB2584664B (en) * 2019-06-10 2023-05-24 Newcells Biotech Ltd Improved retinal organoids and methods of making the same
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
US20220284243A1 (en) * 2021-03-03 2022-09-08 International Business Machines Corporation Ensemble voting classifiers using adjusted thresholds
US12290565B2 (en) * 2021-11-17 2025-05-06 Altrubio Inc. Methods of using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell mediated inflammatory diseases or cancers
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒
CN120682308B (zh) * 2025-06-23 2025-12-02 北京昌盛鸿途生物科技有限公司 牛骨髓肽及其在提高免疫力中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005455A2 (en) * 2003-06-30 2005-01-20 Bio-Technology General (Israel)Ltd. Specific human antibodies
US20090285812A1 (en) * 2008-05-15 2009-11-19 Richard Alvarez Anti-psgl-1 antibodies and methods of identification and use
WO2016007653A2 (en) * 2014-07-08 2016-01-14 Sanford-Burnham Medical Research Institute Psgl-1 modulators and uses thereof
CN108892726A (zh) * 2011-06-13 2018-11-27 艾比吉诺米克斯合作公司 抗psgl-1抗体及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001073028A2 (en) 2000-03-24 2001-10-04 Genetics Institute, Llc A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
CA2561835A1 (en) 2004-03-30 2005-10-13 Den Kgl. Veterinaer-Og Landbohojskole Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
WO2007033959A2 (en) * 2005-09-19 2007-03-29 Vib Vzw Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
WO2011143411A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy for traumatic brain injury
EP2640629A1 (en) 2010-11-18 2013-09-25 Sean Michael Simpson System and method for controlling a transmission of a human-powered vehicle
EP2654781B1 (en) * 2010-12-21 2018-01-24 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification
WO2013057281A2 (en) 2011-10-21 2013-04-25 Transgene Sa Modulation of macrophage activation
WO2015077401A1 (en) 2013-11-20 2015-05-28 Drexel University Compositions and methods for macrophage conversion
US20170306042A1 (en) 2014-08-29 2017-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Immunogenic modulation by endocrine deprivation therapy improves sensitivity of tumor cells to immune mediated lysis
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
KR20230119259A (ko) * 2016-04-15 2023-08-16 이뮤넥스트, 인크. 항-인간 vista 항체 및 이의 용도
GB201611535D0 (en) 2016-07-01 2016-08-17 King S College London Methods and compositions for treating cancer with siglec-9 activity modulators
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
EP3813881A4 (en) 2018-06-29 2022-09-14 Verseau Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATION OF MONOCYTE AND MACROPHAGE INFLAMMATION PHENOTYPES AND IMMUNOTHERAPY USES THEREOF
CA3141334A1 (en) 2019-06-04 2020-12-10 Verseau Therapeutics, Inc. Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005455A2 (en) * 2003-06-30 2005-01-20 Bio-Technology General (Israel)Ltd. Specific human antibodies
US20090285812A1 (en) * 2008-05-15 2009-11-19 Richard Alvarez Anti-psgl-1 antibodies and methods of identification and use
CN108892726A (zh) * 2011-06-13 2018-11-27 艾比吉诺米克斯合作公司 抗psgl-1抗体及其用途
WO2016007653A2 (en) * 2014-07-08 2016-01-14 Sanford-Burnham Medical Research Institute Psgl-1 modulators and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARBARA MUZ等: "Inhibition of P‐Selectin and PSGL‐1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib", BIOMED RESEARCH INTERNATIONAL, vol. 2015, 11 October 2015 (2015-10-11), pages 1 - 8 *
曾宪录, 王晓光, 高艳光, 赵丹丹: "PSGL-1――一种介导白细胞粘附的重要分子", 分子科学学报, no. 02, 23 June 2002 (2002-06-23), pages 22 - 27 *

Also Published As

Publication number Publication date
WO2020247371A1 (en) 2020-12-10
US20220396632A1 (en) 2022-12-15
EP3980463A4 (en) 2023-06-28
US12552873B2 (en) 2026-02-17
IL288510A (en) 2022-01-01
JP2022535550A (ja) 2022-08-09
KR20220042055A (ko) 2022-04-04
CA3141334A1 (en) 2020-12-10
JP2025129213A (ja) 2025-09-04
AU2020288823A1 (en) 2022-02-03
EP3980463A1 (en) 2022-04-13
TW202110891A (zh) 2021-03-16
JP7716992B2 (ja) 2025-08-01
BR112021024242A2 (pt) 2022-04-26
WO2020247371A8 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
JP7716992B2 (ja) 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用
CN114401991A (zh) 用于调节髓系细胞炎性表型的抗siglec-9组合物和方法及其用途
CN113164589A (zh) 用于调节单核细胞和巨噬细胞发炎表型的组合物和方法以及其免疫疗法用途
CN114728057A (zh) 用于调节髓系细胞炎性表型的抗cd53组合物和方法及其用途
US20230348603A1 (en) Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
CN114423452A (zh) 用于调节髓系细胞炎性表型的抗lrrc25组合物和方法及其用途
TW202328196A (zh) 使用vista抗原結合分子的癌症之治療及預防
HK40126807A (zh) Cnx抗原结合分子

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination